Send Message
View as an RSS Feed
  • Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.  [View news story]
    100% of profits and 5% from Aetna from what i can find.
    Sep 19, 2012. 04:17 PM | 1 Like Like |Link to Comment
  • Spectrum Pharmaceuticals (SPPI -3%) reverses early morning gains to trade lower on what appears to be profit taking, despite posting solid Q1 results. Total revenue jumped 36% Y/Y on srong performance by its chemotherapy drug Fusilev, plus better cost controls and aggressive management of operating expenses.   [View news story]
    No reason to be down. Have to add more here. This company has everything going for it and there are too many weak holders or could it be that there is a take over coming ??
    Apr 26, 2012. 03:11 PM | Likes Like |Link to Comment
1 Like